Dialog Box

Skin Health Institute

Clinical Trials Now Recruiting

These study descriptions are intended for potential study participants. Study descriptions for clinicians can be found here.  

If you would like to learn more about any of the studies currently being conducted at the Skin Health Institute, please contact the nominated study coordinator.

If you have any general questions regarding the clinical trials conducted at the Institute, please feel free to contact the Clinical Trials Department at trials@skinhealthinstitute.org.au or by phone on (03) 9623 9439.

RESEARCH STUDY FOR ATOPIC DERMATITIS (28 WEEKS)

Adults 18 years of age or older with chronic atopic dermatitis (AD) diagnosed at least 3 years prior to study start, may qualify to receive approved medication (active study drug) or placebo via injection. Moisturizers and topical corticosteroids will be applied as background treatment during the study.

To be eligible, participants must have an inadequate response to topical medications or otherwise be a candidate for systemic AD treatment. Moderate to severe atopic dermatitis must be present involving 10% or more of the body surface area. As part of the eligibility criteria, sleep quality and itch intensity will be assessed. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 10 times over a period of about 28 weeks.

For more information, please contact:

Principal Investigator:
A/Prof Peter Foley

Sub Investigator:
Dr Charlie Wang
t: 9623 9400
e: cwang@skinhealthinstitute.org.au

Study Coordinator:
Charlotte Harrison-Mullan
t: 9623 9420
e: charrison@skinhealthinstitute.org.au


ORAL MEDICATION STUDY FOR ALOPECIA AREATA

Adults at least 18 years of age with severe or very severe alopecia areata (hair loss), may qualify to receive investigational oral medication (active study drug) or placebo.    

To be eligible, participants must have a current episode of more than 6 months in duration and 50% or more hair loss of the scalp.  There must be no spontaneous improvement (regrowth) over the past 6 months, and the current episode of severe or very severe hair loss must be less than 8 years.  Qualified participants will have regular visits with an experienced research team.  There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 19 times over a period of about 113 weeks.

For more information, please contact:

Principal Investigator:
A/Prof Peter Foley

Sub Investigator:
Dr Charlie Wang
t: 9623 9400
e: cwang@skinhealthinstitute.org.au

Study Coordinator:
Tracy Mallett
t: 9623 9406
e: tmallett@skinhealthinstitute.org.au


scalp psoriasis research study

Adults 18 years of age or older with a diagnosis of plaque psoriasis for at least 6 months, may qualify to receive investigational medication (active study drug) or placebo via injection.

To be eligible, participants must have moderate to severe plaque psoriasis of the scalp (30% or more of scalp area affected) AND moderate to severe plaque psoriasis of the body (10% or more of body surface area involved). Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 15 times over a period of about 76 weeks.

For more information, please contact:

Principal Investigator:
A/Prof Peter Foley

Sub Investigator:
Dr Charlie Wang
t: 9623 9400
e: cwang@skinhealthinstitute.org.au

Study Coordinator:
Irina Danilovich
t: 9623 9448
e: idanilovich@skinhealthinstitute.org.au


HIDRADENITIS SUPPURATIVA RESEARCH STUDY - 1

Adults 18+ years of age with moderate to severe hidradenitis suppurativa (HS) for at least 1 year, may qualify to receive investigational medication (active study drug) or placebo.

To be eligible, participants must have at least 5 inflammatory nodules or abscesses, HS lesions present in at least 2 different areas of the body, and a draining fistula count of 20 or less at the time of study entry. Individuals must also have a history of inadequate response or intolerance to an adequate trial of oral antibiotics for the treatment of HS. Qualified participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Participation can last up to 85 weeks and involve about 17 visits to the study centre.

For more information, please contact:

Principal Investigator:
A/Prof Peter Foley

Sub Investigator:
Dr Charlie Wang
t: 9623 9400
e: cwang@skinhealthinstitute.org.au

Study Coordinator:
Irina Danilovich
t: 9623 9448
e: idanilovich@skinhealthinstitute.org.au



RESEARCH STUDY FOR HIDRADENITIS SUPPURATIVA - 2

Adults aged 18-75 years old with a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least one year, may qualify to receive investigational oral medication (active study drug) or placebo. Participants must agree to use topical antiseptics daily, during study participation.

To be eligible, participants must have HS lesions present in at least 2 distinct areas of the body, with at least 4 inflammatory nodules or abscesses present. Inadequate response to at least a 4-week (28 day) trial of an oral antibiotic for the treatment of HS, is also required. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 10 times over a period of about 26 weeks.

For more information, please contact:

Principal Investigator:
A/Prof Peter Foley

Sub Investigator:
Dr Charlie Wang
t: 9623 9400
e: cwang@skinhealthinstitute.org.au

Study Coordinator:
Irina Danilovich
t: 9623 9448
e: idanilovich@skinhealthinstitute.org.au


ADULT ECZEMA RESEARCH STUDY (65 Weeks)

Adults aged 18 years or older with chronic eczema (atopic dermatitis), may qualify to receive investigational medication via injection (active drug) or placebo, during the initial treatment period. During the second treatment period, individuals who previously received placebo will receive active drug.

To be eligible, participants must have atopic dermatitis with moderate to severe disease severity present at the time of study entry, along with an onset of symptoms at least 2 years ago. Qualified participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 11 times over a period of about 65 weeks. For more information, please contact:

Principal Investigator:
A/Prof Peter Foley

Sub Investigator:
Dr Charlie Wang
t: 9623 9400
e: cwang@skinhealthinstitute.org.au

Study Coordinator:
Charlotte Harrison-Mullan
t: 9623 9420
e: charrison@skinhealthinstitute.org.au


How do I become involved in a clinical trial at the institute?

Anyone can participate in a clinical trial. A referral from a doctor is not necessary.

Contact the Clinical Trials Department directly to inquire about current research projects to determine your suitability
Phone: (03) 9623 9439
Email: trials@skinhealthinstitute.org.au

Donate